Neuromedical Systems, Inc. v. NeoPath, Inc.

I'll research this case to verify the details and build a sourced overview.

Case Overview

The parties were direct competitors, not a patent troll and a target. Neuromedical Systems, Inc. ("NSI") was a Suffern, New York (Rockland County) medical-device company founded in 1988 to develop PAPNET, a computerized system that images Pap-smear slides on an automated microscope, ranks the most suspicious cells using a trained neural network, and displays those cell images to a cytotechnologist for human review. FDA granted premarket approval of the PAPNET Testing System on November 8, 1995, limited to rescreening of slides previously reported negative (adjunctive and quality-control use, not primary screening). NeoPath, Inc., of Redmond, Washington, was founded in 1989 for the same purpose and marketed the AutoPap 300 QC System, which it commercialized as a quality-control rescreener; the FDA approved AutoPap in August 1995, and NeoPath sought a PMA supplement on August 28, 1997 to market an AutoPap Primary Screener version. The 1998 preliminary-injunction opinion described the two firms as "the only two true competitors in a newly developing field, both companies have only one product, and the companies are fighting for the same pool of customers" — a nascent, two-player, PMA-regulated market. (PI opinion, 1998 U.S. Dist. LEXIS 7718; FDA PMA notice, 61 Fed. Reg. 65228 (Dec. 11, 1996); CDC MMWR, Dec. 19, 1997)

The accused technology was NeoPath's AutoPap 300 QC System — specifically its slide-screening algorithms and classifiers. NSI's original July 15, 1996 complaint pleaded patent infringement plus unfair competition and false advertising, alleging NeoPath "willfully misappropriated" PAPNET technology; NeoPath answered and counterclaimed on September 5, 1996, and by agreement the parties dismissed everything but the patent counts, with NSI serving an amended complaint asserting only patent infringement on July 27, 1998. The two asserted patents share a 1988 priority date and a common specification and inventors (Mark R. Rutenberg et al.):

• US 4,965,725 — "Neural Network Based Automated Cytological Specimen Classification System and Method" (filed Apr. 8, 1988; issued Oct. 23, 1990): an automated cytology classifier in which an automated microscope/camera/digitizer feeds a primary classifier that flags candidate objects by a detectable feature (e.g., integrated optical density), and a secondary classifier implemented as a neural computer/neural network distinguishes malignant and pre-malignant cells from look-alikes. The claim NSI relied on at the PI stage was claim 19, a method claim covering primary classification of a randomly arranged specimen to identify locations of interest, followed by secondary classification of those locations "using a neural network computer apparatus."
• US 5,287,272 — "Automated Cytological Specimen Classification System and Method" (filed as a CIP of the '725 application; issued Feb. 15, 1994): the same multi-stage architecture claimed more generically, with a primary classifier and a "secondary adaptive classifier" (claim 4 adds a neural network), plus quality-control-specific claims (claim 23). NSI asserted claim 24, a method claim requiring primary classification by detectable feature and secondary classification of the identified cells "using adaptive processing." (US4965725; US5287272; RPX patent record)

Procedural posture: S.D.N.Y., a denied preliminary injunction, a competing Washington suit, and a bankruptcy that ended the case without a merits ruling. NSI chose S.D.N.Y. as its home forum and filed there on July 15, 1996; NeoPath responded with its own infringement action against NSI on March 31, 1997 in the W.D. Wash., asserting three NeoPath patents — a two-front war that shaped settlement dynamics. In May 1998 the S.D.N.Y. court denied NSI's motion for a preliminary injunction against manufacture and sale of the AutoPap 300 QC System after a two-day evidentiary hearing (cross-examination only, with direct testimony by declaration). The opinion, reported as 1998 U.S. Dist. LEXIS 7718, applies Federal Circuit law under 35 U.S.C. § 283 and turns on likelihood of success: the fight was essentially a claim-construction battle over "neural network" in the '725 patent and "adaptive processing"

I'll dig into the docket history, the PI ruling, the parallel Washington action, and the bankruptcy/asset disposition.

Key legal developments & outcome — chronological

Scope note: The public record for this case is unusually thin because the docket is pre-PACER-electronic (1996–99) and the case ended administratively during a bankruptcy rather than by judgment. I mark unsourced items explicitly. The two best primary sources are (i) the PI opinion, Neuromedical Sys., Inc. v. NeoPath, Inc., 1998 U.S. Dist. LEXIS 7718 (S.D.N.Y. May 1998) (full text PDF), and (ii) NeoPath's and NSI's SEC disclosures (NeoPath 10-Q, Nov. 1998; NSI/TriPath 10-Q, 1999).

1. Filing and initial pleadings

NSI filed on 1996-07-15 in S.D.N.Y., pleading patent infringement plus unfair competition and false advertising and alleging NeoPath "willfully misappropriated" PAPNET technology; relief sought was damages and injunctive relief. NeoPath answered and counterclaimed on 1996-09-05. By agreement, all non-patent claims and counterclaims were dismissed, and NSI served an amended complaint on 1998-07-27 asserting patent infringement only. (NSI 10-Q litigation note)

Date conflict to flag: the trade press reported NeoPath's Seattle suit as filed March 28, 1997 (Gray Sheet/Citeline), while NeoPath's SEC filings say March 31, 1997. The SEC date is the more reliable one, but the discrepancy is unresolved in the public record. I could not verify the W.D. Wash. docket number or the numbers of the three asserted NeoPath patents; do not treat any such number as established.

2. Pre-trial motions of substance

• No motion to dismiss, no § 1404(a) transfer motion, and no motion to stay appears in the accessible record. Notably, NeoPath did not seek transfer to W.D. Wash.; it opened a second front instead — a strategic choice that duplicated discovery and, given NSI's later bankruptcy, left two dormant cases.
• Preliminary injunction (the main event): denied May 1998. Applying Federal Circuit law under 35 U.S.C. § 283 and the four Bio-Technology General factors, the court required a "clear showing" on both validity and infringement. On validity, the court gave "great weight" to the fact that the PTO had upheld both patents in the reexaminations NeoPath itself requested, and rejected NeoPath's reliance on Dr. Taber's testimony and the "Wied reference" as enough to defeat the presumption. The denial therefore turned on infringement, i.e., on whether AutoPap's classifiers were a "neural network" and used "adaptive processing."
• Summary judgment: NSI filed at least two SJ motions in W.D. Wash. — one denied April 1998, a second filed October 1998 and denied. The subject matter of those motions (invalidity vs. non-infringement vs. the '725/'272) is not disclosed in the public filings I could access; treat the specifics as unverified.

3. Claim construction (Markman)

The case never reached a Markman hearing or a Markman ruling. Claim construction was performed only provisionally, in the PI posture, on two claims:

• Claim 19 of the '725 patent — "secondarily classifying such locations of interest using a neural network computer apparatus." The court set out the specification's directed-graph/processing-element/weights definition (col. 4, ll. 19–35) and weighed NSI's expert's "generally understood meaning" against NeoPath's argument that the term must be construed by reference to the patent and its prosecution history.
• Claim 24 of the '272 patent — "secondarily classifying … using adaptive processing." NeoPath argued the phrase had no art-recognized meaning; NSI's expert defined it functionally ("a classifier which has been adaptively trained is by definition an adaptive classifier").

The court's PI analysis is not a binding construction, and because the case died, no court ever issued a final claim construction on either patent. That is the single most important legal gap in this case's history.

4. Discovery milestones of strategic significance

• The accused instrument's source code was the battleground: NSI's expert spent roughly 300 hours reviewing AutoPap software, documentation, and depositions, opining that NeoPath's "fuzzy decision tree" was in substance a neural network and that its "adaptive binary decision tree classifier" used adaptive processing.
• NSI's best documentary evidence came from NeoPath's own regulatory and internal files: the AutoPap Operator's Manual ("adaptive pattern recognition techniques"), the Canadian Health Protection Branch device description ("many adaptive processing … strategies are incorporated"), and an internal Software Requirement Specification ("adaptive training of the processing regime"). This is the classic § 112/lexicography problem NeoPath created for itself — and it is why the PI fight was close enough to require two hearing days.
• The PI hearing itself was structured unusually: direct testimony by declaration, cross-examination only, live. That converted expert declarations into the

I'll research plaintiff-side counsel using the court's PI opinion, docket references, and firm/industry sources.

Counsel of Record — Plaintiff Neuromedical Systems, Inc.

Bottom line: I could not verify the identity of any plaintiff-side attorney from accessible sources, and I am not going to supply names that the record does not support. This is a genuine research dead end rather than a "no counsel appeared" finding, and the distinction matters here.

What I was able to check

Why the names are missing rather than merely unfound

The primary opinions in this case were published in the LEXIS/Westlaw "slip opinion" format, where counsel appears in a header block that the free republished PDFs (a law-firm marketing page and the Harvard caselaw scan) truncated. Every full-text hit I obtained began at the substantive opinion. Since no later merits opinion exists (the case died in bankruptcy; there is no Federal Circuit appeal because the PI was never appealed), there is no appellate caption listing counsel to fall back on — the usual rescue path for pre-ECF patent cases.

What I will not do

I will not populate a counsel table from (a) memory of New York IP boutiques active in the mid-1990s, (b) the counsel who represented NeoPath in the parallel W.D. Wash. actions, or (c) NSI's bankruptcy professionals in the 1999 Chapter 11 — those are different engagements, different firms, and in some cases different parties. Any name produced that way would be fabrication, and it would be indistinguishable in the final work product from a sourced fact. That risk is especially acute here because the prior sections of this case summary are detailed and authoritative-looking; an invented attorney would contaminate the file.

How to close this out (ranked by reliability)

1. Westlaw/Lexis full-document pull of 1998 U.S. Dist. LEXIS 7718. The "Counsel:" field is part of the document and will list lead and local counsel for both sides, with firm names. This is a five-minute check on a paid terminal and is the single highest-yield step.
2. PACER docket for the 1996 S.D.N.Y. civil action, requesting the "parties and attorneys" report rather than the docket sheet; for pre-ECF cases the attorney list is often a separate queryable field even when documents are image-only. NARA's S.D.N.Y. archive (the 1996–99 civil files were transferred) holds the paper docket and the original complaint's signature block.
3. The original July 15, 1996 complaint and the July 27, 1998 amended complaint, whose signature blocks will name trial counsel and, typically, "of counsel."
4. NSI's Chapter 11 filings (S.D.N.Y. Bankr., March 26, 1999) — the schedules and the retention applications will at minimum identify litigation counsel as a creditor/retained professional, which corroborates but does not substitute for item 1.

One accuracy note on the existing draft

The previously generated "Case overview & background" section terminates mid-sentence at "'adaptive processing'" — the '272 claim-construction discussion is unfinished. That is a drafting truncation, not a factual contradiction, but it should be closed before this section is joined to it, since the '272 "adaptive processing" construction was the second of the two grounds on which the PI failed (the court accepted NeoPath's fuzzy-decision-tree/adaptive-non-neural reading). Nothing in my research contradicts the case metadata (caption, court, filing date, patents 4,965,725 and 5,287,272, terminated status).

Counsel of Record for Defendant NeoPath, Inc. — Research Result

Bottom line: I could not verify, from any source I was able to reach, the name of a single attorney who appeared for NeoPath, Inc. in Neuromedical Systems, Inc. v. NeoPath, Inc. (S.D.N.Y.). I am therefore not listing any attorney as counsel of record for the defendant. Naming counsel here would require invention, which the research rules for this case forbid. Below I set out exactly what the accessible record does and does not establish, why the usual sources came up empty, and the specific documents that will resolve the question.

1. What the accessible record establishes about NeoPath's side of the case

These are procedural facts, not counsel facts, but they define the appearances that must exist on the docket:

• NeoPath answered and counterclaimed on September 5, 1996 in the S.D.N.Y. action, so at least one attorney must have entered an appearance for NeoPath by that date. (NeoPath Form 10-Q, Nov. 13, 1998, Note 7 – Litigation; NeoPath 10-K for FY1998)
• NeoPath litigated the preliminary-injunction motion through a two-day evidentiary hearing and the May 1998 denial of NSI's motion, meaning trial counsel and local counsel appearances were active in S.D.N.Y. through mid-1998. (PI opinion, 1998 U.S. Dist. LEXIS 7718)
• NeoPath was simultaneously plaintiff in its own W.D. Wash. action filed March 31, 1997 (and a related second suit in 1998), so it retained separate Washington patent counsel in that period. (NeoPath 10-Q, Note 7)
• The S.D.N.Y. case was removed from the active docket on April 6, 1999 after NSI's Chapter 11 filing, and was later terminated under the AutoCyte–NeoPath IP acquisition agreement — i.e., no merits judgment, and no reported opinion on the merits that would carry a counsel block. (NeoPath 10-K FY1999; NeoPath 10-Q, Note 7)

2. Why counsel could not be sourced (explicit gaps, per the research rules)

• The LEXIS opinion text available online omits the prefatory "Counsel:" field. The copy hosted at marksmannet.com is a LEXIS printout beginning at the heading and the court's recitation of facts; the attorney-appearance block that Westlaw/Lexis normally print before the opinion does not appear in the accessible text. That document therefore cannot support any attorney identification. (1998 U.S. Dist. LEXIS 7718)
• The 1996–1999 S.D.N.Y. docket is not available through the free mirrors I could reach. Pre-2000 civil dockets are generally not in CourtListener's RECAP archive, and I was unable to retrieve a docket sheet for this case before the search budget was exhausted. Practically speaking, the case number itself is unconfirmed in the materials I retrieved; only the filing date (July 15, 1996) and court are documented in NeoPath's SEC disclosures.
• No Law360/Reuters coverage exists for a 1996–1999 patent case of this size, and the trade-press coverage of the PI ruling that I retrieved (Citeline/"The Gray Sheet" abstract; Mealey's-style summary at propertyandcasualty.com) reports the ruling and the injunction denial but does not name trial or local counsel for either side. (Citeline summary; PI summary)
• Sealed/undisclosed filings: nothing in the record I could access suggests NeoPath's appearances were sealed — the gap is archival, not a sealing issue.

3. Names that appear in the record — and why they are not counsel

To prevent misattribution in later sections of this case file, these individuals appear in the sourced materials but are not NeoPath's lawyers:

Anyone populating a counsel table for this case must not draw from this list.

4. Documents that will conclusively answer the question

Because the answer is a pure docket/opinion-block question, it is resolvable — just not with the tools available in this session. In priority order:

1. PACER, S.D.N.Y. — the docket sheet (case filed 7/15/1996; obtain the case number from PACER's civil index by party name for 1996). Docket entry No. 1 (complaint) and the answer/counterclaim filed 9/5/1996 will each carry the attorney caption block; the May 1998 PI order entry and the April 6, 1999 order removing the case from the active docket will show who was still appearing at the end.
2. Westlaw/Lexis full-text of 1998 U.S. Dist. LEXIS 7718 — the prefatory "Counsel:" list at the head of the opinion is the single fastest source, and it is precisely the field missing from the public PDF. Westlaw's docket link (if any) or the "Attorneys" tab would give firm and office.
3. W.D. Wash. docket for NeoPath, Inc. v. Neuromedical Systems, Inc. (filed 3/31/1997) and the 1998 related suit — NeoPath's Washington counsel will appear there, and often the same firm acted as national patent counsel in New York with a separate S.D.N.Y. local counsel.
4. SEC filings with exhibit indices: NeoPath's FY1997/FY1998 10-K and the AutoCyte–NeoPath merger proxy (1999) sometimes identify litigation counsel in the litigation note or in indemnification/escrow provisions. The 10-Q and 10-K I retrieved contain the litigation narrative but no firm names. (10-Q; 10-K)
5. NSI's Chapter 11 docket (Bankr. S.D.N.Y., filed 3/26/1999) — NSI's retention and fee applications would list NSI's counsel, and its schedules of professional fees sometimes reference opposing counsel; this is a secondary route only.

5. Suggested text for this section until verification

Counsel of record for NeoPath, Inc.: not verified. NeoPath appeared and litigated through at least April 1999 (answer and counterclaims filed Sept. 5, 1996; PI opposition and two-day evidentiary hearing, May 1998; case removed from active docket Apr. 6, 1999), so attorney appearances exist on the S.D.N.Y. docket, but the accessible opinion text omits the LEXIS "Counsel" block and the pre-2000 docket was not retrievable. No attorney is named here to avoid an unsourced attribution. Verify via the PACER docket sheet and the Westlaw counsel block for 1998 U.S. Dist. LEXIS 7718.

Flags for the case file: (i) no contradiction with the case metadata was found, but the civil action number is unverified and should be added once PACER is checked; (ii) the existing summary's reliance on 1998 U.S. Dist. LEXIS 7718 is sound for the ruling itself, but that source is not probative on counsel for the reason stated above.